Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 3/20 | 0.62 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.62 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.44 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12791633 | 0.79 | TAAR1 (0.61) | DDB1CRBNTAAR1LMNAKMT2A | |
| SCHEMBL13196912 | 0.77 | TLR7 (0.62) | DDB1CRBNTAAR1LMNAKMT2A | |
| SCHEMBL19585860 | 0.77 | CRBN (1.00) | DDB1CRBNTAAR1 | |
| SCHEMBL6479330 | 0.75 | TAAR1 (0.61) | DDB1CRBNTAAR1APOBEC3AAPOBEC3G | |
| SCHEMBL5851500 | 0.75 | TAAR1 (0.60) | DDB1CRBNTAAR1APOBEC3AAPOBEC3G | |
| SCHEMBL17254609 | 0.75 | TAAR1 (0.60) | DDB1CRBNTAAR1LMNAKMT2A | |
| SCHEMBL29104132 | 0.74 | DAO (0.42) | DDB1CRBNLMNAKMT2ATSHR | |
| SCHEMBL15717250 | 0.73 | APOBEC3A (0.57) | DDB1CRBNAPOBEC3AAPOBEC3GTSHR | |
| SCHEMBL2201558 | 0.72 | TAAR1 (0.55) | DDB1CRBNTAAR1LMNAKMT2A | |
| SCHEMBL31512132 | 0.71 | TAAR1 (0.92) | DDB1CRBNTAAR1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210179627-A1 | 3-(Carboxymethyl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | Grünenthal GmbH (DE) | 2021-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179627-A1 | 3-(Carboxymethyl)-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives | OPRK1, OPRD1, PKD2 | DDB1 167/4885CRBN 2244/4885TAAR1 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.